The long-awaited era of disease-modifying therapy for Alzheimer’s disease has finally arrived and will substantially impact how the disease is perceived and managed, although these new treatments will pose challenges for equitable access. The drugs closest to widespread clinical implementation are lecanemab and donanemab—intravenous monoclonal antibodies that remove β-amyloid plaques from the brain and can slow cognitive and functional decline. Lecanemab was granted accelerated approval by the United States Food and Drug Administration (FDA) in January 2023, and traditional approval in July 2023; marketing authorisation applications have been made to the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency in the UK.